CORRECTED - UPDATE 1-Invitrogen posts profit after year-ago loss

(By including stock option expense of 10 cents per share, corrects adjusted earnings in fourth paragraph so as to compare it to that of Reuters Estimates) (Adds revenue, outlook, patent settlement details)

LOS ANGELES, Feb 5 (Reuters) - Invitrogen Corp (IVGN.O: Quote, Profile, Research), a provider of tools and cultures used in genetic research and drug development, reported a fourth-quarter profit on Tuesday after a loss a year ago, when it took a large impairment charge.

The company's shares, which fell 1.9 percent to close at $83.43 on Nasdaq, were up 1.3 percent at $84.50 after hours.

The Carlsbad, California-based company posted a net profit of $41.1 million, or 83 cents per share, compared with a loss of $100.2 million, or $2.03 per share, a year ago.

Excluding amortization costs, but including 10 cents per share in stock option expense, earnings were $1.05 per share, compared with the average analyst target of 99 cents a share, as compiled by Reuters Estimates.

Revenue rose to $336.4 million from $301.6 million. Analysts had expected $327 million.

Looking ahead to full-year 2008, the company expects revenue to increase in the mid-single digits in percentage terms, while adjusted earnings per share are expected to grow in the high-single to low-double digits.

Separately, Invitrogen and Agilent Technologies Inc (A.N: Quote, Profile, Research) said they have settled three patent infringement lawsuits between Invitrogen and Stratagene Inc, which Agilent acquired in 2007.

Under the agreement, Agilent will make an undisclosed payment to Invitrogen and will discontinue sales of its RNase H minus RT products, and Invitrogen will obtain a license from Agilent and pay an undisclosed royalty to sell its DNA polymerase blend products. (Reporting by Deena Beasley; editing by Phil Berlowitz)